Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Subscribe To Our Newsletter & Stay Updated
